Thalassemia: Verify Whether It Is Research or Treatment Before Applying Abroad
If you see news about a “newly approved drug” or “stopping transfusions” for thalassemia, do not book travel yet. Ask your hematologist and the proposed treatment center to confirm the patient’s type of thalassemia and transfusion needs, whether the proposed care is a locally approved treatment or clinical research, and whether screening, treatment, and follow-up after returning home can all be completed. While waiting for answers, continue transfusions, iron chelation, and organ monitoring as directed by the current care team. If a study requires changes to existing treatment, ask both medical teams to coordinate. For emergencies, seek help immediately as described below.
Key points
- Different types of α- and β-thalassemia and different transfusion needs may call for different medicines or studies. Carriers should first confirm whether they have a problem that needs treatment.
- Approval conditions in the United States, European Union, and China are not interchangeable. Study registration, recruitment advertisements, and marketing approval are also different statuses.
- Gene therapy involves cell collection, manufacturing, conditioning treatment, recovery in hospital, and long-term monitoring. Using the patient’s own cells does not mean there are no serious risks or guarantee lifelong freedom from transfusions.
- Before signing consent forms or paying for travel, obtain written answers about the program’s status, who pays the costs, treatment interruption, and follow-up across borders.
Identify the patient’s condition and treatment pathway first
Ask the current hematologist to document whether the patient has α- or β-thalassemia, their genotype, age, whether they receive regular transfusions, and their recent transfusion volume and pre-transfusion hemoglobin levels. Some patients with non-transfusion-dependent thalassemia may still need transfusions during infections, pregnancy, or surgery. “Not usually receiving regular transfusions” does not mean iron overload monitoring is unnecessary. US National Heart, Lung, and Blood Institute
Write the name provided by the center, the generic name, country, hospital, and hospital site on one page. Ask the center to specify whether this is routine treatment within a locally approved indication, another clinical use, or a specific clinical study. For a study, request its registration number, protocol title, sponsor, ethics review information, center contact, and current screening status. A registry page marked “recruiting” does not mean that the hospital site still has places or that the patient is eligible. Confirm directly with the study team whether it accepts international patients, whether the patient’s age and thalassemia type appear to match, and who is responsible for formal screening.
Can the same treatment be used in different regions?
The table below describes only the listed regulatory scope. It does not mean the patient has been accepted for care or that insurance will pay. Before departure, ask the destination hospital to review the current prescribing information and the patient’s circumstances.
| Pathway | Verified scope of use and questions to ask |
|---|---|
| Mitapivat (AQVESME in the United States) | Used in the United States for anemia in adults with α- or β-thalassemia. This does not mean it is available in China for the same indication. The US prescribing information includes a warning about serious liver cell injury and a restricted-use program: liver function must be tested before and during treatment, and use should be avoided in patients with cirrhosis. Ask the doctor to review other medicines and interactions, and confirm how to seek help and manage dosing if symptoms of possible liver injury occur; see the emergency section below. FDA prescribing information, August 2026 |
| Luspatercept (China) | The indication in the prescribing information included in a company’s 2024 submission to China’s National Healthcare Security Administration is for adults with β-thalassemia who require regular red blood cell transfusions and receive no more than 15 units per 24 weeks. This document is not a verified copy of the latest complete Chinese prescribing information. Ask a doctor or pharmacist to check the currently approved text and local supply and payment conditions. Research involving α-thalassemia cannot automatically be applied to this indication. Submission documents |
| Gene addition: ZYNTEGLO (United States) | Approved in the United States for adults and children with β-thalassemia who require regular red blood cell transfusions. It uses the patient’s own blood-forming stem cells modified by gene addition. The prescribing information warns of a potential risk of blood cancers and requires long-term monitoring. US approval does not mean it is available for routine use in China. FDA product information |
| Gene editing: CASGEVY | The US approval as of July 2026 includes patients aged 2 years and older with transfusion-dependent β-thalassemia. EU product information covers patients aged 12 years and older with transfusion-dependent β-thalassemia who are suitable for a blood-forming stem cell transplant and have no HLA-matched related donor. Age is only one condition; the individual center must also assess organ function and suitability for the full treatment process. FDA; EMA |
Gene addition and gene editing modify cells in different ways. Both commonly require collection of the patient’s own blood-forming stem cells, a wait for manufacturing, conditioning treatment to clear the bone marrow, and then cell infusion and a hospital stay while blood cell production recovers. Conditioning can cause serious infections, bleeding, and impaired fertility. Discuss failed or delayed cell engraftment, long-term safety, and whether fertility can be preserved. Before conditioning, ask the center to explain arrangements for backup cells, manufacturing failure, or treatment that does not work. Even if regular transfusions are no longer needed, existing iron overload and organ problems may still require follow-up. EMA; FDA ZYNTEGLO prescribing information
How to interpret study results
A phase I study of CS-101 base editing conducted in China reported in Nature in 2026 that 5 patients with β-thalassemia stopped receiving transfusions after treatment during the reported follow-up period, with a median follow-up of 23 months. These early results from a small sample cannot guarantee success for an individual or establish long-term safety. The study registration number is NCT06024876. Registration or publication does not prove that places are currently available. Ask the center whether its current program has this exact registration number, whether screening is open, and who is responsible for confirming this. Full paper and figures
When checking promotional figures, first look for four things: the number of people actually treated, their thalassemia type and age, the definition of the primary endpoint, and the length of follow-up. Increased hemoglobin, fewer transfusions, and a continuous period without transfusions are different outcomes. The absence of a reported late complication does not prove it will never occur. Another randomized phase IIa study of vamifeport, lasting 12 weeks and involving 25 adults with non-transfusion-dependent β-thalassemia, found changes in iron-related measures but did not observe a hemoglobin increase reaching 1 g/dL in patients. This does not directly establish clinical benefit or long-term safety. Study paper
What to prepare before applying
Ask the center to confirm accepted file formats and a secure transfer method, then organize:
- Original diagnostic and genetic test reports; age, weight, and any previous transplant or cell therapy.
- Transfusion dates, volumes or units, pre-transfusion hemoglobin, blood group and antibody records, and transfusion reaction records. Ask the center how many years of records it needs.
- Iron chelation medicines, other medicines, and allergy history, along with available records such as ferritin trends, original liver iron and cardiac MRI reports or images, heart and liver function results, and infection assessments.
- Other medical conditions, fertility-related needs, a one-page medical history summary, and the problems the patient hopes to address. For children, a guardian should prepare these materials, with the child participating in discussions according to their age and ability.
If records are incomplete, ask the original hospital to reissue them and tell the study team which results are missing and when they may become available. Do not stop transfusions, conceal complications, or alter records to meet eligibility criteria. After sending the files, ask the receiving department to confirm that they open correctly, have been passed to the screening staff, and who is responsible for the next step and on what date. A successful upload does not mean the patient has been accepted for care.
What to clarify before signing, paying, and traveling
Ask the study team to explain, in language the patient understands, the study’s purpose, known and unknown risks, control groups or random assignment, alternative treatments, visit frequency, how to withdraw, and how samples and data will be used. Keep the signed informed consent form and contact details. In studies covered by China’s Measures for the Ethical Review of Life Science and Medical Research Involving Humans, participants or guardians may withdraw unconditionally at any stage, without first obtaining the study team’s agreement or completing examinations. Conditioning or cell infusion already completed cannot be undone. When withdrawing, patients are advised to voluntarily discuss safety checks, further treatment, and who will take over their care with a doctor. Article 17 of the Ethical Review Measures Also ask whether medication can continue, who pays, and when care returns to the original doctor if the study ends, screening is unsuccessful, or participation stops early.
In drug clinical trials in China, sponsors and trial institutions must not charge participants fees related to the clinical trial. Where the Good Clinical Practice rules for drug trials apply, sponsors must also provide trial medicines free of charge, pay for related medical tests, and cover diagnosis and treatment costs for trial-related harm, along with the corresponding compensation or damages. Clinical research covered by the Regulations on the Administration of Clinical Research and Clinical Translation Applications of New Biomedical Technologies must likewise not charge participants fees related to that research. Ask the institution and ethics committee to explain the program’s nature, applicable rules, and the basis for each charge. Cell therapies do not automatically fall under the same regulatory pathway, and routine care outside the research and costs incurred abroad cannot all be assumed to be free. Article 8 of the Regulations for the Implementation of the Drug Administration Law; Article 20 of the New Technology Regulations; Article 45 of Drug GCP
Ask the center for a written list stating who pays for unsuccessful screening, routine transfusions and iron chelation, hospitalization, complications, interpretation, an accompanying caregiver, accommodation, transportation, extended stays, and tests after returning home. Ask about advance payments, refund conditions, prior insurance authorization, and circumstances in which payment will be denied. Confirm with the insurer whether the condition, hospital, research, and complications are covered. Do not treat an estimate as the final bill. Mark any unconfirmed amounts as “to be confirmed.”
The treatment center must explain, based on the patient’s circumstances, how long cell collection, the manufacturing wait, conditioning, hospitalization, recovery, and follow-up checks will each take, and whether the patient may leave the country. Allow time for delays. Do not buy travel that cannot be refunded or changed before acceptance for care, the treatment window, and financial conditions have been confirmed in writing.
Before returning home, ask the doctors in both countries to agree in writing on: the discharge summary and reports in English; cell product and conditioning records; the latest complete blood count and iron overload results; the medication list; transfusion antibodies and reactions; warning symptoms; the next test date; who receives results; whom to contact about abnormal findings; and arrangements for visits that cannot be completed remotely. Confirm that the doctor at home has agreed to take over care and that the necessary tests and medicines are available locally. If arrangements are not yet in place, first discuss a safe departure date and an interim plan with the treatment center.
When to seek immediate help
If fever, chills, difficulty breathing, chest pain, fainting, or unusual bleeding occurs during treatment or a transfusion, tell the staff immediately. If the patient has already left the hospital and symptoms are severe or worsening quickly, call the local emergency number or go to an emergency department immediately, and report any recent transfusion, bone marrow conditioning, or cell therapy. The emergency number in mainland China is 120. If fever develops after conditioning to clear the bone marrow, contact the treatment team immediately using its emergency contact details, even if there are no other symptoms yet. Do not wait for the next follow-up appointment. If the team cannot be reached immediately, follow the patient’s emergency plan and go to the nearest emergency department at once, reporting the recent conditioning and cell therapy. Call local emergency services if symptoms are severe or worsening quickly. Before discharge, ask the center to write down the patient’s specific fever threshold, 24-hour contact details, and arrangements for the nearest emergency department. While taking US AQVESME, if yellowing of the skin or whites of the eyes, dark urine, nausea and vomiting, or pain in the upper right abdomen develops or worsens, contact the prescribing team immediately and obtain clear dosing instructions before the next dose. If the team cannot be reached immediately, seek urgent medical assessment nearby at once and bring the medication information so the treating doctor can decide what to do. Call local emergency services if symptoms are severe or worsening quickly. US prescribing information CDC transfusion safety information; FDA patient medication information
Frequently asked questions
Do carriers need to apply for gene therapy?
First ask a hematologist to confirm the diagnosis and whether there is anemia that needs treatment. Eligible populations differ between treatments and studies. Carrying a variant alone does not mean cell therapy is needed.
Can I buy plane tickets if the study registry says it is recruiting?
First ask the specific study center to confirm the hospital site, eligibility for international patients, preliminary screening, available places, costs, and appointments. Registry updates may lag, and a recruiting status does not guarantee enrollment.
What if the patient does not meet the study criteria?
Ask the study doctor to document why the patient is ineligible and whether additional records or repeat screening are possible. Discuss current transfusions, iron chelation, and other suitable treatments with the original doctor. Do not change treatment on your own to try to qualify.
Can a medicine approved in the United States be used directly in China?
US approval alone is not enough to determine this. Ask the receiving doctor and pharmacist in China to check the latest local approval, available supply pathways, and the patient’s circumstances. Approval also does not guarantee that the hospital has the medicine or that insurance will pay.
Does stopping transfusions after cell therapy mean the patient is cured?
Stopping transfusions is an outcome that must be interpreted over a defined period. It cannot guarantee lifelong freedom from transfusions or the disappearance of complications. Ask the doctor about long-term blood, iron overload, and organ monitoring.
Can the patient still receive regular care after withdrawing from a study?
In studies covered by the relevant Chinese ethical review measures, participants or guardians may withdraw unconditionally at any stage without prior agreement. It is advisable to discuss a safe handover, follow-up tests, medicine supply, and costs with both the researchers and the original doctor. Conditioning and cell infusion already received cannot be undone.
Can children take part in the decision?
Ask the team to explain in a way the child can understand and check the applicable requirements for informed consent and the child’s own assent. China’s 2026 drug clinical trial rules include specific provisions for minors who can express their wishes and for exceptions. Rules
Sources
Date checked: November 6, 2026. Links in the text point to regulatory agencies, study registries, original papers, and clinical trial rules. Eligibility at a specific center, costs, and the current complete Chinese prescribing information still need to be verified before applying. This article helps patients prepare for discussions with their medical team and does not replace individual medical care.